A CDMO with years of experience is crucial when producing life-changing gene and cell therapies, so choosing the right partner is key. Our experts are here to help you navigate the path to market, for your gene and cell therapy.
With a team comprising over 70 expert gene and cell therapy scientists, we leverage many years of working in this space to build and optimize our gene and cell therapy platform.
Download our brochure to see how we can bring your breakthrough to light
Gene and cell therapies (GCTs) are offering life-changing new treatment options for genetic disorders. Our eBook examines the critical aspects of the development and manufacturing of GCTs and how we can help bring these therapeutics from clinical stages to commercialization.
Process development and analytical development are integral parts of gene therapy manufacturing. This whitepaper explores the analytical and development approaches needed to create a path to success in the clinic and beyond.
From adapting to budget constraints to weathering ongoing supply chain challenges, our industry experts discuss the forces that are driving current changes across the pharma and biotech sectors and share their insights into what we can expect in the market in 2023.
For over 40 years, we've been listening, solving, and guiding our partners' drug projects to success. But what makes us an altogether different kind of CDMO to work with? Find out here.
We explore the key trends shaping the development and manufacturing strategies across the pharmaceutical industry and discuss how strategic partnerships can help build a solid foundation for success.
Pfizer’s manufacturing excellence story can be likened to the sport of crew rowing, learn how the teamwork in rowing mirrors teamworking in pharmaceutical manufacturing.
News & Updates
We are excited to announce our latest investment into our Kalamazoo facility
In this blog we’ll explore the five key measures pharma companies must take to ensure the highest quality supply of their APIs.
Learn about the essential steps developers must take when evaluating a pre-filled syringe system.
When migrating a drug product from vial to PFS, the closure must be screened for suitable parts. Take a look at our blog and checklist detailing what commodities you’ll need and when.